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Ab Immunotherapy is a promising therapeutic
approach for Alzheimer’s disease. Preclinical studies
demonstrate that plaque prevention is possible;
however, the more relevant therapeutic removal of
existing plaque has proven elusive. Monoclonal
antibodies in development target both soluble and
insoluble Ab peptide.We hypothesized that antibody
specificity for deposited plaque was critical for
plaque removal since soluble Ab peptide would
block recognition of deposited forms. We developed
a plaque-specific antibody that targets amodified Ab
peptide (Abp3-42), which showed robust clearance of
pre-existing plaque without causing microhemor-
rhage. Interestingly, a comparator N-terminal Ab
antibody 3D6, which binds both soluble and insol-
uble Ab1-42, lacked efficacy for lowering existing pla-
que but manifested a significant microhemorrhage
liability. Mechanistic studies suggested that the
lack of efficacy for 3D6 was attributed to poor target
engagement in plaques. These studies have pro-
found implications for the development of thera-
peutic Ab antibodies for Alzheimer’s disease.
INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder characterized by two hallmark pathologies, extracel-
lular amyloid plaques and intracellular neurofibrillary tangles.
Strong genetic and biochemical evidence highlights a central
role of the amyloid pathway in the pathogenesis of AD (Hardy
and Selkoe, 2002). The central theme of the ‘‘amyloid
hypothesis’’ is that amyloid deposition is the causative factor
for the initiation of the neurodegeneration cascade, which
includes inflammation, gliosis, neuronal damage, synaptic loss,
and cell loss. Although the exact neurotoxic moiety remains
speculative (monomer, soluble oligomer, or fibril), the neuropath-
ological findings indicate that neurodegeneration of the AD type
occur after initial amyloid deposition. Since monomer Ab and
fibrils are in equilibrium (DeMattos et al., 2002; Tseng et al.,
1999), the deposited plaque probably acts as a reservoir for
soluble Ab, and thus eliminating the deposits would have a908 Neuron 76, 908–920, December 6, 2012 ª2012 Elsevier Inc.multifold benefit through the reduced levels of all possible toxic
forms of Ab (monomer, oligomer, and fibril). Although most of
the early onset familial forms of AD arise due to mutations that
alter the synthesis of Ab to favor increased levels of the Ab42
peptide, the vast majority of cases of idiopathic AD (>95%) are
thought to be due to faulty clearance of the peptide and/or
deposit (Saido, 1998).
Immunotherapy is a promising therapeutic approach focused
on using antibodies to facilitate clearance of the Ab peptide.
Three main mechanisms of action for Ab immunotherapy have
been postulated: soluble equilibrium, phagocytosis, or blockade
of amyloid seeding. The soluble equilibriummechanism is based
upon antibodies neutralizing soluble Ab and shifting the equilib-
rium to favor dissolution (DeMattos et al., 2001).This mechanism
of action is proposed to take place in both the periphery and
central compartments (DeMattos et al., 2001; Yamada et al.,
2009). The phagocytosis mechanism requires antibodies gaining
access to the CNS, where they engage deposited amyloid
(opsonization) and facilitate microglial-mediated phagocytosis
of the plaque (Bard et al., 2000). Finally, others have postulated
that prevention of amyloid deposition may be due to antibodies
binding to early amyloid seeds at a point in the cascade when
these species are present at low abundance, thus preventing
amyloid propagation (Golde, 2003). Thus far, investigators
have focused mostly on N-terminal antibodies, which can bind
either soluble or insoluble forms of Ab, for targeting plaque (Pul
et al., 2011). Prior studies have shown that both active and
passive immunotherapy are effective in reducing amyloid
deposition in transgenic APPmice when performed as a preven-
tativemeasure; however, when these approaches are performed
in aged transgenic mice with pre-existing deposits, they showed
diminished (Levites et al., 2006) or no (Das et al., 2001) efficacy.
We hypothesized that the inability of the N-terminal antibodies to
remove existing plaque was due to antibody saturation with
soluble Ab upon entering the CNS. Thus, nonselective antibodies
will lack sufficient target engagement of deposited plaque and
will not efficiently opsonize the intended target.
In order to test our hypothesis, we developed an antibody that
selectively targets deposited plaque in AD brain. The deposits
found in AD are comprised of a heterogeneous mixture of Ab
peptides (Saido et al., 1996). Although the majority of the Ab
peptides end in the 42nd amino acid, there is an extraordinary
amount of heterogeneity at the amino terminus. One previously
identified truncation is the Abp3-42 (Iwatsubo et al., 1996;
Kuo et al., 1997; Saido et al., 1995). The Abp3-42 peptide arises
due to amino-terminal proteases trimming the first two amino
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Figure 1. Age-Dependent Plaque Lowering
with an N-terminal Ab Antibody
Chronic administration of the N-terminal antibody
3D6 significantly lowers plaque deposition in
PDAPP mice when treatment is initiated at
9 months of age (prevention dosing) but fails to
alter deposition when initiated at 18 months of age
(therapeutic dosing). Nine-month-old PDAPP
mice were treated for 3 months with weekly
intraperitoneal injections of 12.5 mg/kg of 3D6
(n = 18) or vehicle control (n = 22). Time zero group
(9 months old, n = 19) was sacrificed at the onset
of the study.
(A) In hippocampus, there was a 2.6-fold increase
in deposited Ab1-42 from 9 to 12 months and 3D6
treatment significantly lowered the deposited
Ab1-42 by 39% (p = 0.0161, t test).
(B) In cortex, 3D6 significantly lowered Ab1-42 by
69% (p = 0.0001, t test) but was not significantly
different than the time zero (p = 0.3293, t test).
Eighteen-month-old PDAPP mice were treated
for 3 months with weekly intraperitoneal injec-
tions of 12.5 mg/kg of 3D6 (n = 22) or vehicle
control (n = 21). Time zero group (18 months
old, n = 23) was sacrificed at the onset of the
study.
(C) In hippocampus, very little further deposition occurred during the 3 months of treatment (9%) and 3D6 treatment had no significant effect on plaque lowering.
(D) The Ab1-42 in cortex did increase between 18 and 21 months (189%); however, 3D6 treatment had no significant effect at this age. The error bars
represent SEM.
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Anti-Abp3-42 Antibody for Alzheimer’s Diseaseacids from the peptide, followed by cyclization of the functional
group to form a pyrol ring at the amino terminus (pyroglutamate).
This latter modification can occur spontaneously or by the action
of glutaminyl cyclase (Chelius et al., 2006; Cynis et al., 2006).
Early studies demonstrated that the Abp3-42 peptide accumu-
lates early in the deposition cascade (Iwatsubo et al., 1996;
Saido et al., 1995) and the biophysical properties of the Abp3-42
highlighted the aggressive aggregation properties of the peptide
(Schilling et al., 2006; Schlenzig et al., 2009). Since no published
study reported detectable Abp3-42 peptide in a physiological fluid
(i.e., CSF or plasma), this modified Ab peptide is probably plaque
specific and thus an ideal target for immunotherapy.
We generated and engineered high-affinitymurinemonoclonal
antibodies specific for Abp3-x with either minimal (mE8-IgG1)
or maximal (mE8-IgG2a) effector function. These antibodies
robustly labeled deposited plaque in both AD and PDAPP brain
sections and led to a significant reduction of deposited Ab in
an ex vivo phagocytosis assay. Therapeutic plaque-lowering
studies performed with the anti-Abp3-42 antibodies in extremely
aged PDAPP mice (23 to 26 months of age) demonstrated that
mE8 on either maximal or minimal effector function significantly
lowered deposited Ab, whereas mice treated with the N-terminal
antibody 3D6 (mIgG2b), which binds both soluble and insoluble
Ab, lacked efficacy. The underlyingmechanism of action respon-
sible for these contrasting results was identified as a differential
target engagement for the antibodies; the Abp3-42 antibodies
crossed the blood-brain barrier and bound to the deposited
Ab, whereas the 3D6 antibody lacked plaque binding, a finding
thought to be due to its saturation with soluble Ab in brain. Impor-
tantly, microhemorrhage analyses demonstrated that the Abp3-42
antibodies did not increase this adverse event, whereas mice
treated with 3D6 had extensive microbleeds. These mechanisticfindings have important implications for the interpretation of
current clinical studies and the development of second genera-
tion antibodies for AD immunotherapy.
RESULTS
Prevention and Therapeutic Immunotherapy with an
N-terminally Directed Ab Antibody that Recognizes All
Forms of Ab
Plaque-lowering studies were performed in PDAPP transgenic
mice to investigate the ability of an amino-terminally directed
Ab antibody to either prevent or lower existing amyloid deposits.
Themonoclonal antibody 3D6, themurine equivalent of bapineu-
zumab, binds to both soluble and insoluble Ab at the extreme
amino terminus (Ab1-5) with an affinity of 3–5 nM (koff 2 3
104/s at 25C). Two study paradigms were investigated, either
plaque prevention (ages 9 to 12 months) or a therapeutic study
exploring attenuation of ongoing deposition or clearance of pla-
ques (ages 18 to 21months). For both studies, a group of PDAPP
mice were sacrificed at study initiation (time zero) to determine
the extent of existing pathology prior to dosing. PDAPP trans-
genic mice were treated for 3 months with weekly injections of
3D6 at 12.5 mg/kg (500 mg) or vehicle (PBS). An analysis of
the 9-month-old PDAPP mice treated for 3 months with 3D6
demonstrated a significant prevention of Ab deposition in
hippocampus (40%, p < 0.0161, Figure 1A) and cortex (69%,
p < 0.0001, Figure 1B). In contrast, the aged PDAPPmice treated
from 18 to 21 months showed no effect on levels of existing
deposited Ab in either the hippocampus (p = 0.7441, Figure 1C)
or cortex (p = 0.5959, Figure 1D). A comparison of the time zero
(18 months) versus the vehicle-treated (21 months) animals
demonstrates that deposition had reached a plaque plateau inNeuron 76, 908–920, December 6, 2012 ª2012 Elsevier Inc. 909
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Figure 2. Low Levels of Abp3-42 Peptide in
Plaque Can Facilitate Ex Vivo Antibody-
Mediated Phagocytosis
The Abp3-42 peptide is present in both PDAPP and
AD brains at low levels and opsonization with
a monoclonal antibody in an ex vivo phagocytosis
assay results in significant Ab clearance.
(A) Abp3-42 concentration in brain lysates from AD
(n = 10) and PDAPP mice (12 and 23 months old;
n = 6) were determined by ELISA.
(B) The prevalence of the Abp3-42 peptide in
AD and PDAPP brain was calculated relative to
total Ab42.
(C and D) Histological analyses of deposited Ab
from a 24-month-old PDAPP mouse with either
3D6 (C) or mE8 (D).
(E and F) Histological analysis of AD brain showed
similar staining for 3D6 (E) and mE8 (F).
(G) An ex vivo phagocytosis assay was conducted
on AD brain sections. Prior to adding primary
murine microglia, AD brain sections (20 mm) were
preincubated with the following antibodies: 3D6
(Ab1-x), 21F12 (Abx-42), 2G3 (Abx-40), mE8-IgG1
(Abp3-42), mE8-IgG2a (Abp3-42), or control IgG2b
(same effector function as 3D6). After 24 hr incu-
bation, the Ab1-42 was determined by ELISA. Each
bar represents the mean ± SEM, n = 4 wells for
each treatment except the no cells control (n = 35).
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Anti-Abp3-42 Antibody for Alzheimer’s Diseasehippocampus prior to the initiation of dosing, a finding that
suggests that the deposition in the aged PDAPP (>18 months)
may be representative of a similar plaque plateau implied by
cross-sectional amyloid PET studies in cohorts of patients with
early to midstage AD. PDAPP cortical Ab deposition is signifi-
cantly lower than hippocampus and the rate of accumulation in
the aged PDAPP mice between 18 and 21 months increased
2-fold, thereby suggesting a delay in reaching the plaque
plateau in this tissue. These plaque-lowering studies confirm
previously published literature showing beneficial effects of Ab
immunotherapy when used for prevention of amyloid deposition
(Bard et al., 2000, 2003) but not for clearance of established
deposits.
Generation and Ex Vivo Characterization of Anti-Abp3-42
Antibodies
Previous studies demonstrated that themodified Abp3-42 peptide
accumulates early in the deposition cascade (Iwatsubo et al.,
1996; Saido et al., 1995) and probably was specific for plaque
(i.e., no soluble peptide found in physiological fluids). We immu-
nized mice with the Abp3-42 peptide and subsequently screened
clones for Abp3-x binding and counterscreened against Ab1-42. A910 Neuron 76, 908–920, December 6, 2012 ª2012 Elsevier Inc.low-affinity Abp3-42 monoclonal antibody
was affinity matured to yield the high-
affinity (140 pM) anti-Abp3-x antibody
mE8 (koff < 1 3 10
5/s at 25C). Charac-
terization of the binding properties of
mE8 demonstrated that it specifically
recognized the modified amino terminus
of Abp3-x in that it does not recognize
full-length Ab or unmodified Ab3-x (seeFigure S1 available online). In order to evaluate the impact of
effector function on in vivo plaque clearance, mE8 was made
in both mouse IgG1 (minimal effector function) and IgG2a
(maximal effector function) isotypes. The affinity-matured mE8
was first used to investigate levels of the Abp3-42 peptide in
PDAPP and AD brain lysates. ELISA analyses demonstrated
that low levels of the Abp3-42 peptide could be detected in both
PDAPP and AD brains (Figure 2A). Interestingly, the prevalence
of the Abp3-42 peptide was quite low (0.6%) with respect to
the overall amount of Ab42 deposited in these brains (Figure 2B).
The analyses also showed an age-dependent accumulation of
Abp3-42 peptide in PDAPP brains that increased 47-fold between
12 and 23 months of age (Figure 2A). The similar prevalence of
Abp3-42 in AD patients and PDAPP mouse brains demonstrates
that our transgenic model recapitulates the generation of this
neuropathological target.
Immunohistochemical analyses were performed with anti-
Abp3-x antibodies in order to determine whether the epitope is
accessible in aged PDAPP and AD brain sections. Robust Ab
staining was observed in brain sections from a 24-month-old
PDAPP mouse with 3D6 (Figure 2C) and more discrete staining
was observed for the mE8 antibody (Figure 2D). Histological
Neuron
Anti-Abp3-42 Antibody for Alzheimer’s Diseaseanalyses performed on fresh-frozen AD brain resulted in similar
staining between the 3D6 and mE8 antibodies, where again
the labeling was more intense and widespread for the 3D6 anti-
body (Figures 2E and 2F). We next investigated whether the rela-
tively low levels of the Abp3-42 antigen would be sufficient to
enable opsonization and Fc receptor-mediated phagocytosis.
Ex vivo phagocytosis studies were performed with exogenously
added Ab antibodies preincubated with AD brain sections that
were subsequently treated with primary murine microglial cells
(Figure 2G). The following murine Ab antibodies were investi-
gated: 3D6 (anti-Ab1-x, IgG2b), mE8 (anti-Abp3-x, IgG1), mE8
(anti-Abp3-x, IgG2a), 21F12 (anti-Abx-42, IgG1), 2G3 (anti-Abx-40,
IgG1), and amurine control antibody (IgG2b, same effector func-
tion as 3D6). Note that the antibodies 21F12 and 2G3 bind
deposited Ab quite poorly even though they robustly bind soluble
Ab, a result likely due to epitope shielding that occurs once the
Ab peptide is incorporated into the fibrils. Analysis of the remain-
ing Ab1-42 present in the tissue sections demonstrated that the
3D6 and mE8 (minimal or maximal effector function) amino-
terminal antibodies significantly facilitated clearance of depos-
ited plaque (p < 0.001). The Abp3-x antibody with maximal
effector function (mE8, IgG2a) cleared significantly (p < 0.001)
more plaque than the Abp3-x antibody with minimal effector func-
tion (mE8, IgG1). The control antibodies (21F12, 2G3, or control
murine IgG2b), which lack the ability to bind the target, did not
alter Ab clearance relative to the microglia cells alone. These
results demonstrate that exogenous addition of the amino-
terminal antibodies 3D6 and mE8 (minimal or maximal effector
function) facilitated the targeting of microglia to the AD plaque.
Interestingly, the ability of the amino-terminal antibody 3D6 to
opsonize the plaque was no greater than the Abp3-x antibodies,
even though the antigen for 3D6 is significantly more abundant.
Thus, targeting evenminor components of the AD plaque is suffi-
cient to drive microglial recognition and phagocytic clearance.
In Vivo Plaque-Lowering Studies: Therapeutic Study
The ability of the murine anti-Abp3-x antibodies with minimum
(IgG1) and maximum (IgG2a) effector function to lower existing
plaque was investigated in PDAPP mice. We performed a thera-
peutic plaque-lowering study in 23- to 24-month-old PDAPP
mice with the following antibodies: negative control antibody
(IgG2a), 3D6, mE8-IgG1, and mE8-IgG2a. Aged PDAPP mice
were injected intraperitoneally with 12.5 mg/kg of each antibody
weekly for 3 months. A time zero group of mice was necropsied
at the beginning of the study in order to determine the initial pla-
que load at 24.5 months of age. Analysis of the hippocampal
guanidine lysates from the time zero and antibody control (26
to 27 months old) cohorts showed a nonsignificant increase in
deposited Ab42, thereby demonstrating that the brains of the
PDAPP mice were at the plaque plateau (Figure 3A). Similar to
our previous studies, treatment with the 3D6 antibody had no
effect on amyloid levels in hippocampal lysates. In contrast,
treatment with either Abp3-x antibody, minimal or maximal
effector function, resulted in significant Ab lowering as
compared to the IgG control antibody (p < 0.01 and p < 0.001,
respectively). The mE8-IgG1 and mE8-IgG2a lowered the Ab42
by 38% and 53%, respectively. The Abp3-x antibody with
maximal effector function trended to being more efficaciousthan the minimal effector function antibody; however, this differ-
ence did not reach statistical significance. Importantly, the mE8-
IgG2a antibody significantly lowered Ab42 by 30% in the
hippocampus as compared to the time zero mice (t test;
p < 0.0066), thus demonstrating clearance of existing Ab
deposits. The analyses of the cortical guanidine lysates yielded
very similar outcomes with the exception that only the mE8-
IgG2a with maximal effector function significantly decreased
Ab42 deposition (Figure 3B). ELISA analysis for plasma Ab40
and Ab42 revealed significantly elevated levels in 3D6-treated
mice but no difference in the mE8- or control-treated mice
(Figures 3C and 3D), which probably reflects the plaque-specific
nature of Abp3-x and the resultant low levels of this species in
plasma. Analysis of the plasma IgG levels at the conclusion of
the study showed similar mean levels between the 3D6, mE8-
IgG1, and mE8-IgG2a dose groups (Figure 3E). Ab-lowering
effectiveness was also investigated by histological end points.
Morphological differences in the deposited plaque were ob-
served in the animals treated with the Abp3-x antibodies when
brain sections were immunostained with multiple anti-Ab anti-
bodies (Figure 4A). Animals treated with mE8-IgG2a consistently
had areas of plaque deposition in the CA1 and CA3 regions that
histologically appeared blurred and less defined; a similar but
less dramatic effect was observed in mE8-IgG1-treated animals.
However, an analysis of the percent area of the hippocampus
covered by Ab immunostaining showed no significant difference
among the treatment groups (Figure 4B). Likewise, analysis of
the total amyloid load or microglia counts revealed no significant
treatment effects (Figures S2 and S3). Note that the PDAPP
transgenic model mainly develops diffuse plaque. Thus, in this
model, the anti-Abp3-x antibodies predominantly reduced Ab
as pre-existing diffuse plaque.
The Abp3-x antibody-mediated clearance of existing plaque
was highly repeatable. Since plaque-lowering studies have
proven to be challenging to repeat in transgenic mice, we per-
formed an additional dose-response study with our mE8
antibody. Sixteen-month-old PDAPP mice were injected subcu-
taneously weekly for 6 months with 1.5, 4, or 12.5 mg/kg of
mE8-IgG2a or 12.5 mg/kg of the control antibody. This study
demonstrated that significant additional deposition occurred
during the 6 months of antibody treatment, wherein the depos-
ited Ab nearly doubled in hippocampus (p < 0.001, Figure 5A)
and tripled in cortex (p < 0.001, Figure 5B). A significant dose-
dependent decrease in Ab42 was observed for the mE8-
IgG2a treatment in both hippocampus (p < 0.0001, Figure 5A)
and cortex (p < 0.0073, Figure 5B). In hippocampus, the 4 and
12.5 mg/kg doses significantly lowered deposited Ab42 by
31% (p < 0.001) and 39% (p < 0.001), respectively. The
1.5 mg/kg dose of mE8-IgG2a was a nonsignificant 15% lower.
The analyses of the cortical lysates yielded very similar results,
with the exception that the 4 mg/kg dose did not achieve sig-
nificance. These results demonstrated that the anti-Abp3-x-
mediated plaque lowering is robust and repeatable.
Abp3-x mAb Reduces Deposited Amyloid without
Inducing Microhemorrhage
An additional histological study was performed on brain sections
from the 3 month therapeutic study (Figure 4) to investigateNeuron 76, 908–920, December 6, 2012 ª2012 Elsevier Inc. 911
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Figure 3. Chronic Administration of an Anti-
Abp3-42 Antibody Significantly Reduces
Pre-existing Deposited Ab In Vivo
A chronic study demonstrates that Abp3-42 anti-
bodies on either minimum or maximum effector
function significantly lower existing plaque in aged
PDAPP mice. PDAPP mice (23 to 24 months old)
were treated for 3 months with weekly intraperi-
toneal injections of 12.5 mg/kg of the following
antibodies: m3D6 (anti-Ab1-x, IgG2b, n = 30), mE8-
IgG1 (anti-Abp3-x, n = 27), mE8-IgG2a (anti-Abp3-x,
n = 23), or control IgG2a (n = 27). A time zero group
(24.5 months old, n = 15) was sacrificed at the
onset of the study.
(A) In hippocampus, PDAPP mice treated with
mE8-IgG1 and mE8-IgG2a resulted in significantly
decreased Ab42 deposition (p < 0.01 and p <
0.001, respectively; Tukey’s post hoc) as com-
pared to the control IgG2a-injected animals. Mice
treated with mE8-IgG2a had 30% lower Ab42 in
the hippocampus as compared to the time zero
mice (t test; p < 0.0066).
(B) Cortical extracts from PDAPP mice treated
with mE8-IgG2a demonstrated a significant
decrease for Ab42 deposition (p < 0.05; Tukey’s
post hoc) as compared to the control IgG2a-in-
jected animals.
(C and D) Plasma ELISAs for Abx-40 (C) or Abx-42
(D) revealed a significant increase for both
peptides in the 3D6-treated mice (p < 0.001,
Tukey’s post hoc) and no difference for the mE8
treatments.
(E) An ELISA conducted on plasma from
the conclusion of the study showed no dif-
ference in final IgG levels. The error bars repre-
sent SEM.
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Anti-Abp3-42 Antibody for Alzheimer’s Diseasewhether the mechanism of action of the anti-Abp3-x antibodies
that leads to plaque lowering in aged PDAPP mice would also
result in an exacerbation of CAA-related microhemorrhage. We
have previously demonstrated that chronic treatment with 3D6
significantly increases the incidence ofmicrohemorrhage (Racke
et al., 2005). In this study, we again observed a dramatic increase
in microhemorrhage with 3D6 treatment (p < 0.001) (Figure 4C).
Significantly, the 3D6-dependent exacerbation of microhemor-
rhage occurred even in the absence of plaque lowering. In
contrast, treatment with either mE8-IgG1 or mE8-IgG2a did not
significantly increase microhemorrhage, even though these
Abp3-x antibodies were able to reduce deposited Ab. These
results demonstrate that treatment with the Abp3-x antibodies
in aged PDAPP mice with maximal plaque loads was able to
reduce existing deposited Ab without CAA-related microhemor-
rhage liability.912 Neuron 76, 908–920, December 6, 2012 ª2012 Elsevier Inc.In Vivo Plaque-Lowering Studies:
Prevention Study
To investigate whether the Abp3-x anti-
body mE8-IgG2a would be efficacious
at preventing plaque deposition, we per-
formed a study in 5.5-month-old PDAPP
mice, an age before the initiation of Abdeposition, with the following antibodies: negative control anti-
body (IgG2a), 3D6, and mE8-IgG2a. A time zero group and an
additional parallel untreated group of transgenic mice were
incorporated in the study to determine the time course of depo-
sition. As expected, the time zero animals (5.5 months of age)
lacked deposited Ab42 (Figure 5C). In hippocampus, a dramatic
accumulation of deposited Ab42 occurred throughout the study
period (45-fold) with the majority depositing during the latter
2 months of the study (80% between months 10.5 and 12.5).
Consistent with previous reports for similar N-terminal anti-
bodies, treatment with 3D6 resulted in a significant 68%
decrease of hippocampal Ab42 (p < 0.001) as compared to the
control IgG, although levels were higher than the untreated
animals sacrificed at 10.5 months of age. The mE8-IgG2a
treatment resulted in a nonsignificant 30% decrease in Ab42
as compared to the control IgG-treated mice. Similar results
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Figure 4. Chronic Administration of an Anti-
Abp3-42 Antibody Alters Deposited Plaque
without Exacerbating Microhemorrhage
Histological analyses were performed to investi-
gate whether chronic antibody treatment in aged
PDAPP mice resulted in altered Ab deposition or
microhemorrhage. The study parameters are
described in Figure 3.
(A) Brain sections were immunostained with bio-
tinylated anti-Ab antibodies 3D6, 10D5, and mE8.
Morphological differences in the deposited plaque
were consistently observed in the animals treated
with the Abp3-x antibodies, wherein the plaque
appears less defined in areas of the CA1 and CA3.
High magnification from the boxed areas high-
lights the altered appearance of the deposited Ab
in the CA1 (3D6 and 10D5 stains).
(B) The percent area of Ab immunoreactivity in the
hippocampus (3D6 immunostain) was measured
(mean with the SEM).
(C) Microhemorrhage was investigated by
surveying 2 mm of brain tissue for hemosiderin-
positive cells. No increase in hemosiderin-positive
cells was observed in mice treated with mE8-IgG1
(10 ± 5) or mE8-IgG2a (97 ± 85), whereas a highly
significant increase in 3D6 (2939 ± 617)-treated
mice was observed relative to control (19 ± 9). The
inset is a representative picture of a menigeal
vessel surrounded by several hemosiderin-posi-
tive cells (Perls stain).
Neuron
Anti-Abp3-42 Antibody for Alzheimer’s Diseasewere observed in the cortical extracts from these mice (Fig-
ure 5D). These results demonstrate that while the phagocytic
mechanism of the Abp3-x antibody is able to clear deposited
Ab, it is less effective at preventing Ab42 deposition in young
PDAPP mice. In contrast, the N-terminal antibody 3D6, which
binds soluble and insoluble Ab, reveals an opposite pattern of
efficacy (no clearance of established plaque and strong pre-
vention of deposition), thereby suggesting that the major mech-
anism of action for these two antibodies is different.Neuron 76, 908–920, DDelineation ofMechanism of Action
We sought to determine the mechanism
of action responsible for the differential
effects on plaque lowering observed for
the Abp3-x and 3D6 antibodies by per-
forming in vivo target engagement
studies. Our original hypothesis was that
antibodies such as 3D6, which binds to
both soluble and insoluble Ab, would
have decreased plaque-lowering ability
relative to plaque-specific antibodies
since the 3D6 antibody (or any other anti-
body that binds soluble Ab) would
become saturated with soluble Ab prior
to reaching the deposited plaque. Bio-
tinylated 3D6, mE8, or control IgG were
peripherally injected into aged PDAPP
mice to histologically determine the
amount of antibody crossing the blood-
brain barrier and binding to depositedAb. The amount of target engagement was first evaluated in
aged PDAPP mice receiving a single injection of the antibodies
(40 mg/kg) and subsequently sacrificed 3 days later (Figure 6A,
top). Animals injected with 3D6 had plaque labeling that was
limited to a narrow area along the hippocampal fissure, whereas
mice injected with mE8 displayed robust plaque labeling
throughout the hippocampus and cortical regions. We next per-
formed a subchronic study wherein aged PDAPP mice received
four antibody injections over 21 days and the animals wereecember 6, 2012 ª2012 Elsevier Inc. 913
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p < 0.05 Figure 5. Dose Response and Prevention
Studies with an Anti-Abp3-42 Antibody
Aged PDAPP mice treated with the anti-Abp3-42
antibody demonstrate a dose-dependent re-
duction of plaque, whereas the same antibody
failed to significantly prevent deposition in young
PDAPP mice. PDAPP mice (16 months old) were
treated for 6 months with weekly subcutaneous
injections of mE8-IgG2a at the following doses:
12.5 mg/kg (n = 23), 4 mg/kg (n = 23), or 1.5 mg/kg
(n = 21). A time zero group (16 months old, n = 30)
was sacrificed at the onset of the study.
(A) In hippocampus, PDAPP mice treated with the
varying doses of mE8-IgG2a showed a significant
dose-dependent decrease in deposited Ab1-42
(p < 0.0001, ANOVA). Animals dosed with 4 and
12.5 mg/kg of mE8c had significantly lower
deposited Ab1-42 as compared to the control
IgG2a-injected animals (p < 0.001, Tukey’s
post hoc).
(B) In cortex, a less significant dose-dependent
decrease in deposited Ab1-42 (p < 0.0073, ANOVA)
was observed. Animals dosed with 12.5 mg/kg of
mE8-IgG2a had significantly lower deposited
Ab1-42 as compared to the control IgG2a-injected
animals (p < 0.05, Tukey’s post hoc). A plaque
prevention study was conducted wherein
PDAPP mice (5.5 months old) were treated for
7 months with weekly subcutaneous injections of
12.5 mg/kg of the following antibodies: m3D6
(anti-Ab1-x, IgG2b, n = 29), mE8-IgG2a (anti-
Abp3-x, n = 29), and control IgG2a (n = 29). A time
zero group (5.5 months old, n = 30) and an
untreated group of PDAPP mice (10.5 months of age, n = 27) were sacrificed to follow the deposition of Ab1-42 during the course of the study.
(C) In hippocampus, PDAPP mice treated with 3D6 had a significant decrease in deposited Ab1-42 at the conclusion of the study (68%; p < 0.001, Tukey’s post
hoc). Preventative treatment with mE8-IgG2a had a nonsignificant 30% lowering of deposited Ab1-42.
(D) In cortex, similar plaque prevention was observed for mice treated with 3D6 (52%; p < 0.001, Tukey’s post hoc), whereas mE8-IgG2a failed to significantly
prevent deposition (21%). The error bars represent SEM.
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bottom). Similar to the acute study, the mE8 antibody robustly
engaged deposited plaque, whereas 3D6 engagement was
limited to the hippocampal fissure. To distinguish whether
repeat administration of the anti-Ab at high doses would result
in greater target engagement, brain sections from a subgroup of
animals from both studies (acute and subchronic, n = 3 to 4 per
group) were evaluated. As shown in the figure insets, the repeat
dosing of high concentrations of antibodies resulted in an
increase in target engagement for 3D6 along the hippocampal
fissure (p = 0.0111) and a nonsignificant increase in hippo-
campal target engagement for mE8. To better quantify the
target engagement in hippocampus and cortex, a separate
acute study was performed in aged PDAPP mice (Figure 6B).
In both hippocampus and cortex, the Abp3-x antibody mE8
engaged significantly more target than 3D6 (p = 0.0005, p =
0.0408, respectively). Target engagement for 3D6 was again
limited to the hippocampal fissure area. A nontransgenic rat
pharmacokinetic study was performed to investigate whether
3D6 and mE8 access the CNS to a similar degree (Figure 6C).
Although the majority of the CSF IgG concentrations overlap-
ped for the two antibodies, the mE8 did have slightly higher
levels that reached significance (p = 0.034). The difference in
CSF levels was driven by higher plasma exposures, as914 Neuron 76, 908–920, December 6, 2012 ª2012 Elsevier Inc.evidenced by no difference in the CSF:plasma ratio. Next, we
investigated whether soluble Ab1-40 could inhibit antibody
binding to deposited plaque in a histological experiment (Fig-
ure 6D). Ab antibodies were preincubated with increasing
concentrations of soluble Ab1-40 prior to performing histology
on brain sections from an aged PDAPP mouse. Preincubation
of mE8 with soluble Ab1-40 had no effect on plaque binding,
whereas the soluble Ab1-40 in a concentration-dependent
manner dramatically inhibited 3D6’s ability to bind deposited
Ab. Taken together, these results strongly suggest that the
3D6 antibody becomes saturated with soluble Ab in the CNS
and thus can not engage the deposited Ab, whereas the pla-
que-specific Abp3-x antibody mE8 robustly engages the depos-
ited amyloid. Lastly, to investigate the mechanism of plaque
clearance with anti-Abp3-x antibodies, we examined brains at
the conclusion of the 6 month chronic study in aged PDAPP
for histological signs of phagocytosis. Consistent with a phago-
cytotic mechanism of action, confocal microscopy illustrates
convergence of activated microglia with deposited Ab in the
anti-Abp3-x-treated (Figure S3) but not in control IgG2a-treated
PDAPP mice. These results imply that chronic treatment with
Abp3-x antibodies significantly decreases amyloid deposition in
aged PDAPP mice in a manner that is at least partially depen-
dent on effector function.
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Figure 6. Ab Antibody In Vivo Target
Engagement Studies in Aged PDAPP Mice
(A) Aged PDAPP mice (n = 4 to 5 per group)
received a single 40 mg/kg intraperitoneal injec-
tion of the following biotinylated Ab antibodies:
3D6 (anti-Ab1-x), mE8 (anti-Abp3-x), and control
IgG. The antibody in vivo target engagement
(plaque binding) was assessed histologically
(strepavidin-HRP followed by DAB) 72 hr after
injection (acute treatment, top). A subchronic
3 week study was conducted with the same anti-
bodies (40 mg/kg weekly, 4 total doses, n = 7 to 9
per group) and the target engagement and
CSF:plasma ratio was evaluated as above (sub-
chronic treatment, bottom). A subgroup from the
acute and subchronic studies (n = 3 to 4 per group)
were evaluated within the same histological run in
order to determine the relative target engagement
in hippocampus (shown in the figure insets).
(B) To quantify the target engagement, six aged
PDAPP mice received a single 40 mg/kg injection
of biotinylated 3D6 or mE8 and the total area of
plaque labeling in hippocampus and cortex
was measured histologically (strepavidin-HRP
followed by DAB). When normalized for each
respective target, the anti-Abp3-x mE8 antibody
showed significantly more target engagement in
hippocampus (p = 0.0005) and cortex (p = 0.0408).
The error bars represent SEM.
(C) A nontransgenic rat 24 hr PK study performed
with biotinylated Ab antibodies 3D6 (anti-Ab1-x)
and mE8 (anti-Abp3-x) showed a slight but sig-
nificant difference in plasma (p = 0.0012) and CSF
antibody levels (p = 0.034). No significant dif-
ference was observed in the CSF:plasma ratio.
(D) Antibody binding specificity in the presence of
increasing concentrations of soluble Ab1-40
was determined histologically for 3D6 and mE8.
Biotinylated antibodies (3 mg/ml) were pre-
incubated with soluble Ab1-40 (0, 0.5, 5.0, and
10 mg/ml) prior to performing immunohistochem-
istry on brain sections from aged PDAPP mice.
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Current clinical immunotherapy trials are generally thought to be
an important test of the amyloid hypothesis. The available sup-
porting evidence for each compound, both preclinical and clin-
ical, provides an indication to what extent the clinical trials will
have tested the amyloid hypothesis, as opposed to merely
testing the individual therapeutic antibodies. Prior preclinical
studies have shown that both active and passive immunother-
apies were effective in lowering plaque in transgenic APP mice
when performed as a preventative measure; however, when
these approaches were performed as a therapeutic in aged
transgenic mice, they lacked efficacy in terms of amyloid reduc-
tion (Das et al., 2001; Levites et al., 2006). Moreover, prevention
of amyloid deposition with antibodies to the N terminus of Ab
was still observed in APP mice that lack FcRg, which is required
for antibody-induced phagocytosis by microglia (Das et al.,
2003). This result implied that phagocytosis was not required
for prevention of amyloid deposition by passive immunotherapy,
at least with nonselective N-terminal anti-Abeta mAbs. Severalpossible explanations were postulated to account for the lack
of efficacy in aged animals, including deposited target over-
whelming small amounts of CSF IgG, altered plaquemorphology
resulting in antibody resistance, or senescence of the microglial
phagocytotic machinery (Das et al., 2001). Our studies with the
N-terminal antibody 3D6, the murine equivalent of bapineuzu-
mab, replicated the literature wherein 3D6 significantly pre-
vented plaque deposition yet consistently failed to alter deposi-
tion when administered to mice with extensive pre-existing Ab
plaque.
We hypothesized that the lack of antibody engagement with
amyloid deposits (plaque binding and phagocytosis) was due
to saturating levels of soluble Ab in the vicinity of plaques and
the lack of target engagement was the key underlying mecha-
nism hindering Ab clearance with N-terminal antibodies that
bind both soluble and insoluble Ab. To circumvent the hypothe-
sized antibody saturation effect, we developed antibodies that
are highly selective for deposited plaque. Our initial biochemical
characterization of AD and PDAPP brains revealed a low preva-
lence of our intended immunotherapeutic target (Abp3-42 0.6%Neuron 76, 908–920, December 6, 2012 ª2012 Elsevier Inc. 915
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have been reported in AD brain by other groups (Schilling
et al., 2008). Subsequent histological analyses demonstrated
that the Abp3-42 peptide was well distributed among the majority
of the plaques, thus presenting an effective target for opsoniza-
tion, FcR engagement, and microglial phagocytosis.
In addition to the roles of epitope abundance and antibody
affinity in triggering effector function, antibody isotype has also
been shown to be critically important (Nimmerjahn and Ravetch,
2005). Utilizing Abp3-x antibodies with isotypes of varying effector
potency, we demonstrated that robust clearance of existing
plaque was in agreement with reported ability to engage acti-
vating Fc receptors. Additionally, the plaque-lowering ability
of the Abp3-x antibody was shown to be highly repeatable in
a dose-response study. Differences were observed in the effi-
cacy of plaque lowering between hippocampus and cortex for
the anti-Abp3-x antibodies that may be a result of the lower net
levels of deposited Ab or possibly the delay in deposition in
this tissue relative to hippocampus (and thus less modified Ab
species). Interestingly, in contrast to 3D6 and other N-terminal
antibodies, the Abp3-x antibody failed to show significant plaque
lowering when used as a preventative measure. We attribute this
observation to the lack of modified Ab target in the young PDAPP
mice during the course of treatment prior to amyloid formation
and during initial deposition. Additionally, the lack of efficacy in
the prevention paradigm for the anti-Abp3-x antibody suggests
that Abp3-x is not the major nucleating species for initial plaque
deposition. Since the Abp3-42 peptide appears to be solely
located in deposits (Bibl et al., 2012), the only mechanism of
action through which the Abp3-x antibodies could lead to plaque
lowering is through phagocytosis of existing plaque. Consistent
with this mechanism, we observed that treatment with Abp3-42
antibodies led to increased microglial colocalization with
amyloid deposits in vivo. In regard to Ab deposition, one critical
parameter that is different between AD patients and PDAPP
mice is the overall amount of Ab deposited per unit time. Imaging
studies with amyloid PET ligands have demonstrated that plaque
accrual in AD patients is minimal after diagnosis (Ossenkoppele
et al., 2012; Villemagne et al., 2011), whereas PDAPP mice have
robust deposition even during the plateau phase (i.e., the time
frame after the logarithmic phase of deposition), in which the
Ab levels can increase by more than 30% in as little as 3 months.
Thus, plaque lowering in PDAPPmice probably represents a very
high hurdle since the final ‘‘net’’ plaque loweringwill be a function
of clearance of pre-existing plaque in addition to the newly
formed plaque during the course of the study.
The central tenant of our original hypothesis was that
antibodies that bind both soluble and insoluble forms of Ab will
become saturated in the CNS prior to reaching deposited Ab.
The blood-brain barrier only allows0.1%of peripheral antibody
to gain access to the central compartment. Moreover, the CNS
has 20- to 67-fold higher levels of soluble Ab relative to the
periphery (Giedraitis et al., 2007;Mehta et al., 2001). Studies per-
formed byMaggio and colleagues have demonstrated first-order
rate constants for soluble monomer Ab associations with plaque
(Esler et al., 1999; Tseng et al., 1999). Since Ab can associate
and dissociate from existing plaque, as deposition increases, it
will correspondingly drive concentrations of soluble monomer916 Neuron 76, 908–920, December 6, 2012 ª2012 Elsevier Inc.Ab higher in the microenvironment. Indeed, these equilibriums
were previously observed in PDAPP transgenic mice (DeMattos
et al., 2002). These findings suggest that as deposition increases,
a dense cloud of soluble Ab envelopes the plaque and acts as
a barrier to prevent plaque binding for any Ab antibody that binds
to the soluble form (Figure 7). A recent study utilizing microdialy-
sis found decreased soluble Ab concentrations in ISF during the
course of plaque deposition, a finding suggestive of plaque
sequestration (Hong et al., 2011). These seemingly contrasting
results probably arise due to the measurement of soluble Ab in
different locales; the microdialysis studies measure a macroen-
vironment, whereas the proposed increased soluble pool of Ab
would be highly localized to the microenvironment of the plaque
(i.e., microns). This hypothesis is consistent with a recent publi-
cation showing that soluble oligomeric Ab species are present
at high concentrations in the immediate vicinity of amyloid pla-
ques (Koffie et al., 2009). Additionally, enhanced plaque removal
has been demonstrated with an N-terminal antibody similar to
3D6 in an inducible APP transgenic mouse model, wherein
soluble Ab was genetically reduced (Wang et al., 2011). In
support of our hypothesis, the in vivo target engagement studies
showed a near complete lack of plaque binding for 3D6, yet the
plaque-specific Abp3-x antibody showed widespread binding to
amyloid deposits in the hippocampus and cortex. The same
3D6 antibody was successful in an ex vivo phagocytosis model
in which exogenous antibody facilitated plaque removal;
however, in this experimental paradigm, high levels of antibody
(10 mg/ml) were added to a static system in which soluble Ab
effects would be negated. Additionally, 3D6 was efficacious
when administered in a prevention paradigm, a scenario that
would precede the establishment of high concentrations of
solublemonomer associated with plaque and indeed a paradigm
that previous reports (Das et al., 2003) have suggested may not
primarily involve a phagocytic mechanism.
Previous studies have demonstrated that treatment of aged
APP transgenic mice with certain anti-Ab N-terminal and
C-terminal antibodies will lead to an increase in CAA-related
microhemorrhage (Pfeifer et al., 2002; Racke et al., 2005;
Wilcock et al., 2004). The microhemorrhage liability first
observed preclinically in transgenic mice has translated into
the clinic for both active immunization (Boche et al., 2008) and
passive immunization with the N-terminal antibodies bapineuzu-
mab and gantenerumab (Black et al., 2010; Ostrowitzki et al.,
2012; Sperling et al., 2011). The clinical manifestation of micro-
hemorrhage appears to be linked with another vascular abnor-
mality, vasogenic edema (Sperling et al., 2011). Although the
mechanism underlying this potential adverse event is unclear,
two nonmutually exclusive hypotheses have been proposed
based upon the transgenic mouse studies: the redistribution of
Ab into the cerebral blood vessels (Wilcock et al., 2004) or the
direct binding of antibodies to existing CAA (Racke et al.,
2005). Biochemical and histological analyses have demon-
strated that Abp3-42 is a constituent of CAA in both AD patients
and aged PDAPP mice (data not shown). Our studies demon-
strated that the Abp3-x antibodies did not exacerbate microhe-
morrhage yet were able to significantly remove existing plaque.
Strikingly, the 3D6 antibody induced a clear increase in microhe-
morrhage; however, the antibody did not remove plaque. These
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Figure 7. Summary of Mechanism of Action
Insights for Plaque Binding Anti-Ab Anti-
bodies
Cartoon model that summarizes the important
mechanistic insights for plaque-derived soluble
equilibriums’ effect on Ab immunotherapy. The
cartoon depicts two different physiological situa-
tions in brain, the presence of low (A) or high (B–D)
plaque loads, which are thought to represent the
very earliest phase of AD (10 years prior to diag-
nosis) and AD at first diagnosis, respectively.
(A) In the earliest phase of disease, an antibody
that binds both soluble and insoluble Ab will
probably be efficacious as it may engage the
sparsely deposited plaque and lead to its removal
(prevention). Conversely, these antibodies may
also act through the direct binding to soluble Ab,
either monomer or oligomeric complexes within
the CNS, to facilitate the prevention or elimination
of amyloid-promoting Ab seeds. During this early
phase, an antibody that specifically targets plaque
will only be effective at preventing and removing
deposited Ab if its epitope is present at a suffi-
cient level.
(B) During stages of the disease in which extensive
plaque deposition has already occurred, an anti-
body that binds both soluble and insoluble Ab will
probably be ineffective at lowering pre-existing
plaque due to limited target binding (i.e., becomes
saturated with soluble Ab).
(C) Additionally, if the soluble binding antibody is
of weak affinity, it may result in redistribution of
soluble Ab into the vasculature as CAA.
(D) Lastly, an antibody that is plaque specific will
probably be highly efficacious at removing exist-
ing plaque due to the high levels of target
engagement.
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of existing plaque and increased microhemorrhage are
mechanistically linked. The current anti-Abp3-x results clearly
demonstrate that plaque can be removed without this adverse
event. The question then becomes how does 3D6 increase
microhemorrhage?
We propose that the mechanism responsible for the microhe-
morrhage event is dependent upon antibody binding specificity
and affinity toward its epitope (Figure 7). The 3D6 antibody has
low nanomolar binding affinities toward both soluble and
insoluble Ab and the antibody has a fairly fast off rate in vivo
(dissociation half-life15 min). As our in vivo target engagement
data suggest, 3D6 probably becomes saturated as it enters the
cloud of Ab surrounding the plaque. Since there is no physical
tethering to keep the antibody:Ab complex in place, the complex
moves away from the plaque by interstitial fluid dynamics. Due to
the off rate, the antibody releases the Ab peptide, where it then
begins to deposit along the vasculature as cerebral amyloid angi-Neuron 76, 908–920, Dopathy. Thus, 3D6 is likely to redistribute
the soluble Ab from the cloud surrounding
plaque to the vasculature with a resulting
increase in CAA. Previous studies have
demonstrated significant positive correla-tionsbetween theamount of vascularCAAandmicrohemorrhage
in transgenic mice and humans (Winkler et al., 2001; Yates et al.,
2011). Additionally, autopsy results from the active vaccination
studies in AD patients have shown a dramatic increase of CAA
in areas of the brain that had significant plaque removal (Boche
et al., 2008). The characterization of antibodies generated by
active vaccination has shown that the majority of antibodies
produced by the polyclonal response are of low affinity and
directed against the N-terminus of Ab (Lee et al., 2005). Other
monoclonal antibodies in addition to bapineuzumab currently
being tested in the clinic support this hypothesis: an antibody
that binds very weakly to soluble Ab (Bohrmann et al., 2012)
has presented with a similar microhemorrhage liability (Ostro-
witzki et al., 2012), whereas several other antibodies that bind
strongly to soluble Ab appear to lack the adverse event (Adolfs-
son et al., 2012; Farlow et al., 2012; La Porte et al., 2011).
Our results have significant implications for the clinical
development of N-terminal nonplaque-selective antibodies.ecember 6, 2012 ª2012 Elsevier Inc. 917
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was based upon preclinical studies in transgenic mice and, as
such, their respective clinical implementation has been modeled
upon the phagocytosis mechanism, maximal effector function,
and studies performed in patients with extensive deposition. A
small neuroimaging study performed with the PET ligand PIB
did report a significant amyloid reduction (25%) in patients
receiving the monoclonal antibody bapineuzumab as compared
to placebo controls (Rinne et al., 2010). It is important to highlight
that 17% of the perceived amyloid reduction was due to an
atypical rise in the PIB signature in the small (n = 7) placebo
cohort (Ossenkoppele et al., 2012). We demonstrate that
N-terminal antibodies that bind both soluble and insoluble Ab
fail to lower existing Ab deposition in our preclinical PDAPP
transgenic model in line with previous reports in the literature.
Many studies have demonstrated that N-terminal Ab antibodies
prevent plaque deposition (Bard et al., 2000; Schenk et al., 1999;
Schroeter et al., 2008) including studies in FcRg knockout mice
(Das et al., 2003). These, along with our current results, suggest
that it is unlikely that plaque prevention is due to phagocytosis. A
more plausible mechanism for N-terminal Ab antibodies would
be their direct binding to soluble Ab, either monomer or oligo-
meric complexes within the CNS, to facilitate the prevention or
elimination of amyloid-promoting Ab seeds. The anti-seeding
and spreading mechanism would not be dependent upon
effector function and thus if correct should enable the generation
of a safer therapeutic antibody. This strategy is already being
clinically implemented withMABT5102A, also known as Roche’s
Crenezumab, a humanized N-terminal Ab antibody engineered
as a minimal effector function IgG4 (Adolfsson et al., 2012).
Indeed, testingmultiple humanized anti-Ab antibodies that target
different mechanisms of action in the clinic (mono or combina-
tion therapy) will be important for the field, especially as clini-
cians begin investigating the presymptomatic populations.
In summary, these studies have demonstrated that the devel-
opment of plaque-specific Abp3-x antibodies that lack binding to
soluble Ab peptides leads to significant engagement of Ab
deposits (i.e., plaque binding) and to the subsequent removal
of existing plaque without a microhemorrhage liability. The sepa-
ration of microhemorrhage from the plaque removal event
suggests a possible redistribution mechanism of soluble Ab to
the vasculature may be responsible for the adverse event. These
mechanistic insights lay the foundation for the generation and
engineering of safe and highly efficacious Ab antibodies for the
removal of existing plaque in Alzheimer’s patients. This is an
important goal since biochemical and neuroimaging data
demonstrate the presence of extensive plaque deposition in
AD patients some 10 years prior to first memory complaint
(Jack et al., 2010; Morris and Price, 2001; Price et al., 2009)
and indeed by the time of diagnosis, plaque deposition is already
reported to be at or near maximal levels.EXPERIMENTAL PROCEDURES
Transgenic Mice
Multiple colonies of PDAPP mice were utilized for the current studies. PDAPP
line 1683 heterozygous for the APPV717F transgene wasmaintained on amixed
outbred background as previously described (Johnson-Wood et al., 1997).918 Neuron 76, 908–920, December 6, 2012 ª2012 Elsevier Inc.The phenotype of the PDAPP line 1683 colony began to change wherein
plaque deposition initiated at later ages, and there was a dramatic increase
in the variability of deposited Ab in middle-aged mice (8–14 months old). A
new PDAPP colony (line 6042) was established through an inbreeding exercise
wherein mice were inbred from selected litters that maintained decreased vari-
ability in both soluble and insoluble Ab. The plaque deposition phenotype of
the inbred PDAPP line 6042 was similar to the originally described PDAPP
colony (Games et al., 1995). All experiments were performed in accordance
with the Institutional Animal Care and Use Guidelines for Eli Lilly.
Phagocytosis Model
Frozen brain tissue of an AD patient was embedded in M-1 Embedding Matrix
at 20C, sectioned to 20 mm, mounted on poly-D-lysine-coated cover glass
(15 mm), and placed in 24-well tissue culture plates. Sixty four consecutive
sections were positioned in the same order as sectioned and were incubated
with or without antibodies (10 mg/ml, 500 ml, 1 hr, room temperature). The
control IgG utilized in the experiment was balanced with the 3D6 effector func-
tion (i.e., IgG2b); experiments performed with control IgG1 or IgG2a result in
very similar values (data not shown). Primary murine microglia (8 3 105 cells,
500 ml) were then added to sections and incubated for 24 hr at 37C. Each
section with antibody treatment was followed by an untreated sister section.
At the end of incubation, media were removed and tissue sections and cells
were homogenized with 5.2 M guanidine buffer (300 ml), diluted 103 and
1003 with PBS buffer containing 0.5 M guanidine, 0.05% Tween20 and
0.25% casein, and Ab1-42 concentration quantified by ELISA. To account
for differences in the amount of deposited Ab in different sections, we normal-
ized each unknown treatment by the untreated sister section. Data were
directly plotted in GraphPad Prism and analyzed by one-way ANOVA with
Newman-Keuls posttest.
Histology Ex Vivo
To evaluate the relative amount of deposited full-length Ab and N3pGlu
peptide in PDAPP, cryostat serial coronal sections (10 mm thick) from
a 24-month-old PDAPP mouse were incubated with 10 mg/ml of biotinylated
murine antibodies 3D6 (anti-Ab1-x), mE8 (anti-Abp3-x), or negative control
murine IgG. Ex vivo histological analyses of deposited Ab in AD brain was
investigated on cryostat serial sections (20 mm thick) incubated with 3 mg/ml
of the biotinylated murine antibodies. Secondary HRP reagents specific
for biotin were employed and the deposited plaque was visualized with
DAB-Plus (DAKO). Brain sections from PDAPP or AD incubated with control
biotinylated murine IgG were devoid of staining (data not shown).
Histology In Vivo Target Engagement
The acute target engagement of biotinylated 3D6, mE8, or control murine IgG
were evaluated in 24- to 29-month-old PDAPP mice (line 6042, homozygous).
Aged PDAPP mice (n = 4 per treatment) were injected intraperitoneally with
40 mg/kg of antibody and, 72 hr later, the brains were harvested for
immunohistochemistry. For subchronic injection studies with the biotinylated
antibodies, 16- to 19-month-old PDAPP mice (line 6042, homozygous) were
injected intraperitoneally weekly with 40mg/kg of each antibody for four doses
and the animals (n = 4 per treatment) were sacrificed 3 days after the final injec-
tion. At the conclusion of either study, mice were perfused with heparinized
saline and the brain was flash frozen for histology. Cryostat serial coronal
sections (12 mm thick) were stained with Dako streptavidin HRP followed by
DAB plus reagent to visualize the murine biotinylated antibody that had
crossed the blood-brain barrier and engaged the deposited plaque. To quan-
tify the total area of hippocampus and cortex occupied by either antibody, we
injected 19- to 22-month-old PDAPP (line 6042, homozygous) mice intraperi-
toneally with 40 mg/kg of either antibody (n = 6) and, 72 hr later, the animals
were sacrificed and the amount of in vivo target engagement was measured
(as described above). Brain sections were also immunostained with exoge-
nous biotinylated 3D6 or mE8 in order to determine the total amount of depos-
ited full-length Ab or Abp3-x, respectively. The total area immunostained with
the exogenous antibodies represents the total area of target possible in
each section that the antibody in vivo could have bound; thus, the in vivo target
engagement area was normalized to the total amount of target possible for
either antibody.
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The detailed protocols for the design and analysis of the chronic Ab-lowering
studies in PDAPP transgenic mice are found in the Supplemental Experimental
Procedures.
Statistics
Statistical analyses were performed using the Prism GraphPad software
unless noted otherwise. For most studies, the one-way ANOVA was used to
determine the significance (p values) for multiple cohort studies (>2).
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